HALO Q3 Earnings Call Highlights Royalty Growth and Patent Dispute

Halozyme raised 2026 revenue guidance to $1.86B–$1.925B and royalty guidance to $1.235B–$1.255B; Q3 revenue rose 39% to $493M, beating the $482M consensus, while royalties climbed 44% to $341M and non-GAAP EPS of $2.39 topped the $2.29 estimate. Management cited expanding partner royalties and development pipelines, including a projected $1B Hypercon royalty opportunity, while noting a Dutch court found its EP622 patent infringed and restricted KEYTRUDA Qlex in eight European markets. The company ended September with $1.08B in cash and marketable securities, repurchased $400M of shares during 2026, and issued $1.5B of convertible notes.

Analysis

The key underwriting issue is whether subcutaneous conversion becomes a durable royalty escalator or merely shifts existing demand between delivery formats. For HALO, conversion can add royalty-bearing volume without requiring the underlying drug market to expand; for partners, the offset is possible cannibalization of IV sales and the execution burden of retraining clinics and patients. Track conversion against total franchise growth, not as a standalone adoption statistic. If uptake stalls before partners’ stated ambitions, current royalty growth may prove front-loaded.

The European KEYTRUDA Qlex ruling is more a distribution and bargaining catalyst than evidence of a global threat to MRK: the U.S. patent record differs, and appeals extend the uncertainty. Near term, restrictions could redirect some European patients to IV administration rather than materially impair the drug franchise. HALO’s upside from enforcement depends on remedies and licensing outcomes, neither quantified here.

Over 1–3 months, February’s 2027 outlook should test royalty durability and product-level assumptions. Over 6–18 months, pipeline additions diversify the royalty base only gradually; Hypercon and Aerocon remain development-stage options, not near-term earnings support. HALO’s cash and buybacks cushion investment needs, but convertible maturities and net leverage make capital allocation and potential dilution relevant if growth disappoints. Contrarian angle: headline royalty growth may overstate organic demand growth, while the market may underweight the value of format conversion if adoption broadens across partner franchises.

Key Decisions for Investors

• HALO: Favor a staged long on weakness rather than chasing the raised outlook. Reassess after February guidance; require continued royalty growth and evidence that conversion is expanding without weakening underlying partner-product demand. Falsifier: conversion plateaus or 2027 royalty assumptions imply a sharp deceleration.
• Avoid a broad MRK short based on the European ruling alone. Treat it as a jurisdiction-specific risk; revisit only on adverse appeal developments, broader manufacturing constraints, or evidence of meaningful franchise disruption.
• Monitor BMY and ROP partner disclosures for IV-to-SC conversion and total franchise trends. Rising conversion with stable or growing total demand supports HALO’s royalty thesis; conversion accompanied by shrinking franchise sales weakens it.
• Do not capitalize Hypercon/Aerocon projections as current earnings. Treat 2027 Hypercon trial starts and subsequent clinical execution as milestone alerts; delays or weak partner commitment would reduce the value of HALO’s longer-dated pipeline optionality.